Market News

15 posts
Algernon Pharmaceuticals (CSE:AGN) to conduct DMT Stroke Program study

" Claritas Pharmaceuticals (TSXV:KLY) has added Professor Salvatore Cuzzocrea, Ph.D. to their Board of Directors

Claritas Pharmaceuticals (KLY) has added Professor Salvatore Cuzzocrea, Ph.D. as an independent member of the company’s board of directors, effective immediately.
Algernon Pharmaceuticals (CSE:AGN) to conduct DMT Stroke Program study

" Claritas Pharmaceuticals (TSXV:KLY) announces additional program to reduce the spread of COVID-19

Claritas Pharmaceuticals, Inc. (KLY) has initiated a second development program with R-107, the company’s proprietary nitric oxide-releasing compound.
Kalytera CEO issues letter to shareholders

" Claritas Pharmaceuticals (TSXV:KLY) collaborating with Salzman Group and other companies to accelerate the development of R-107

Claritas Pharmaceuticals has entered into a strategic collaboration agreement with Salzman Group, to expedite the development of R-107.
Sonoro Gold (TSXV:SGO) begins metallurgical testing at Cerro Caliche

" Osisko (TSXV:ODV) announces high grade drill results at Cariboo Gold Project

Osisko Development (ODV) announces continued high-grade drill results at Cariboo Gold Project in central British Columbia.
PharmaDrug (CSE:BUZZ) signs supply agreement with global cannabis supplier

" Guardian Capital Group (TSX:GCG) acquires BNY Mellon’s Canadian wealth management business

Guardian Capital Group (GCG) has acquired BNY Mellon’s Canadian wealth management business.
Kalytera CEO issues letter to shareholders

" Claritas Pharmaceuticals (TSXV:KLY) to focus on developing R-107 as a therapy for vaccine-resistant COVID-19, Influenza, and other viral infections

Claritas Pharmaceuticals (KLY) will focus primarily on the development of its nitric oxide-releasing compound, R-107.
covid test - The Market Herald Canada

" Therma Bright (TSXV:THRM) enters into clinical trial agreement for its AcuVid COVID-19 rapid antigen test

Therma Bright will conduct a clinical study of the company’s AcuVid TM rapid antigen test.
Vaxil (TSXV:VXL) provides update from the conclusion of COVID-19 challenge study

" Vaxil (TSXV:VXL) provides update from the conclusion of COVID-19 challenge study

Vaxil Bio (VXL) reports results of a previously disclosed COVID-19 vaccine candidate challenge experiment and the strategy going forward.
The company that’s bringing customers to crypto … fast, easy & secure

" Bitcoin Trust (TSX:BITC.UN) fully invested on first day of trading

Ninepoint Partners LP announced today that Bitcoin Trust (BITC.

" Health Canada approves Pfizer-BioNTech COVID-19 vaccine

On Wednesday, Canada took a major step towards bringing COVID-19 under control after its national health regulator approved Pfizer’s vaccine.